NCT07201649 Roles of Hepatic Insufficiency, Hepatic Fibrosis, and Inorganic Pyrophosphate in the Progression of Arterial Calcifications
| NCT ID | NCT07201649 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Centre Hospitalier Universitaire de Nice |
| Condition | Liver Cirrhosis |
| Study Type | INTERVENTIONAL |
| Enrollment | 95 participants |
| Start Date | 2025-11-24 |
| Primary Completion | 2028-11-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 95 participants in total. It began in 2025-11-24 with a primary completion date of 2028-11-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Individuals with metabolic syndrome (MetS), particularly those with type 2 diabetes (T2D), and/or metabolic dysfunction-associated steatohepatitis or MASH face an elevated risk of major cardiovascular events (MACE). We showed decrease plams level of PPi in patients with liver cirrhosis. We hypothezised that liver transplant should block AC and restore PPi plasma level.
Eligibility Criteria
Inclusion Criteria: * everyone requiring liver transplantation for the treatment of a chronic liver disease Exclusion Criteria: * MELD score \>25, viral replication
Contact & Investigator
Guillaume FAVRE, PhD
PRINCIPAL INVESTIGATOR
CRC, Néphrologie - CHU de Nice - Hôpital de l'Archet
Frequently Asked Questions
Who can join the NCT07201649 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Liver Cirrhosis. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07201649 currently recruiting?
Yes, NCT07201649 is actively recruiting participants. Contact the research team at favre.g@chu-nice.fr for enrollment information.
Where is the NCT07201649 trial being conducted?
This trial is being conducted at Nice, France.
Who is sponsoring the NCT07201649 clinical trial?
NCT07201649 is sponsored by Centre Hospitalier Universitaire de Nice. The principal investigator is Guillaume FAVRE, PhD at CRC, Néphrologie - CHU de Nice - Hôpital de l'Archet. The trial plans to enroll 95 participants.